Testosterone Enanthate and Progesterone HRT Interaction

Why These Two Drugs Get Prescribed Together

Clinicians pair testosterone enanthate with progesterone in several distinct populations. The combination appears in transgender hormone therapy, perimenopausal women receiving both androgens and progestogens, and men on testosterone replacement who also use progesterone for sleep or neuroprotection.

In gender-affirming care, the Endocrine Society's 2017 Clinical Practice Guideline recommends testosterone as first-line masculinizing therapy for transgender men [1]. Progesterone may be added for endometrial protection in patients who have not undergone hysterectomy, or for its anxiolytic and sleep-promoting properties. A 2019 review in The Journal of Clinical Endocrinology & Metabolism noted that progesterone's role in transmasculine care remains "insufficiently studied but clinically common" [2].

For cisgender women in perimenopause, low-dose testosterone (typically 1 to 5 mg weekly, far below the 100 to 200 mg doses used in male hypogonadism) may be co-prescribed with micronized progesterone. The International Menopause Society's 2019 position statement noted that testosterone therapy "may be considered for postmenopausal women with hypoactive sexual desire disorder after other causes are excluded" [3]. Progesterone serves its standard role of opposing estrogen's endometrial effects in these patients.

Some male hypogonadism protocols include low-dose progesterone (100 to 200 mg oral at bedtime) to address insomnia, based on progesterone's conversion to the neurosteroid allopregnanolone. This practice lacks large-scale trial data but has appeared in clinical case series [4].

Pharmacokinetic Profile: How Each Drug Is Metabolized

Neither drug meaningfully alters the other's absorption, distribution, or clearance. That is the core pharmacokinetic takeaway.

Testosterone enanthate is an intramuscular depot formulation. After injection, esterases cleave the enanthate ester, releasing free testosterone. Testosterone undergoes hepatic metabolism primarily through CYP3A4, with contributions from CYP2C9 and CYP2C19 [5]. It is also reduced by 5-alpha reductase to dihydrotestosterone (DHT) and aromatized by CYP19A1 to estradiol. The FDA-approved label for testosterone enanthate (Delatestryl) lists no specific drug interaction warnings related to progesterone [6].

Oral micronized progesterone (Prometrium) undergoes extensive first-pass hepatic metabolism, also primarily via CYP3A4. Its major active metabolite, allopregnanolone, is responsible for the sedative and anxiolytic effects that distinguish oral from vaginal or transdermal progesterone [7]. The Prometrium prescribing information does not list testosterone or androgens as interacting drugs [8].

Both drugs are CYP3A4 substrates, which raises a theoretical question: could they compete for the same enzyme? In practice, the answer is no at clinical doses. Testosterone enanthate produces serum testosterone levels of 300 to 1,000 ng/dL (physiologic range), and micronized progesterone at 100 to 200 mg/day produces serum levels of 5 to 30 ng/mL [7]. These concentrations are orders of magnitude below the threshold needed for clinically meaningful CYP3A4 substrate competition. Neither drug is a CYP3A4 inhibitor or inducer at therapeutic doses [5][8].

Pharmacodynamic Interactions: Where the Overlap Actually Matters

The clinically relevant interaction between testosterone enanthate and progesterone is pharmacodynamic, not pharmacokinetic. Three overlapping effect pathways deserve attention.

Fluid retention. Testosterone promotes sodium and water retention through activation of the renin-angiotensin-aldosterone system and direct tubular effects [9]. Progesterone, while antimineralocorticoid at high doses, can contribute to fluid shifts during early therapy. The practical concern is peripheral edema, weight gain, and blood pressure elevation in the first 4 to 8 weeks of combination therapy. A 2020 retrospective cohort study of 231 transmasculine patients on testosterone found that 12.6% reported peripheral edema within the first three months [10].

Sedation and CNS effects. Oral micronized progesterone generates allopregnanolone, a potent positive allosteric modulator of GABA-A receptors [7]. Testosterone itself does not produce direct sedation, but supraphysiologic levels can cause mood lability, irritability, or depressive symptoms. The combination may produce additive CNS effects in sensitive patients, particularly if progesterone is dosed in the morning rather than at bedtime.

Dr. Joshua Safer, executive director of the Mount Sinai Center for Transgender Medicine and Surgery, has noted: "When we add progesterone to testosterone regimens, the most common patient-reported effect is improved sleep, but clinicians should ask about daytime drowsiness and adjust timing accordingly" [11].

Erythropoiesis. Testosterone stimulates erythropoietin production and directly activates erythroid progenitor cells. Polycythemia (hematocrit above 54%) occurs in approximately 5% to 18% of men on testosterone replacement therapy, according to a meta-analysis of 30 randomized controlled trials published in The Lancet Diabetes & Endocrinology (N=1,642) [12]. Progesterone does not independently raise hematocrit, so this interaction is not additive. The monitoring requirement for hematocrit is driven by testosterone alone.

Monitoring Protocol for the Combination

Structured lab work reduces the risk of complications. The following schedule reflects Endocrine Society and American Urological Association (AUA) recommendations adapted for combination use [1][13].

Baseline (before starting): Complete blood count (CBC) with hematocrit, comprehensive metabolic panel (CMP), lipid panel, total and free testosterone, estradiol, progesterone level, liver function tests (LFTs), and blood pressure measurement.

Weeks 8 to 12: Repeat CBC (hematocrit check is the priority), total testosterone trough level (drawn the morning before the next injection), and progesterone level if using oral formulation. Assess for edema, mood changes, and sedation. Blood pressure recheck.

Months 3 to 6: Repeat full panel. The AUA's 2018 guideline recommends checking hematocrit at 3 to 6 months after testosterone initiation and annually thereafter [13]. Add a lipid panel at 6 months, as testosterone can reduce HDL cholesterol by 5 to 15% [14].

Annually after stabilization: CBC, CMP, lipid panel, testosterone trough, and clinical assessment. Adjust testosterone dose if hematocrit exceeds 50%. The Endocrine Society recommends dose reduction or temporary cessation if hematocrit exceeds 54% [1].

Dr. Shalender Bhasin, professor of medicine at Harvard Medical School and principal investigator of multiple testosterone trials, has stated: "The 54% hematocrit threshold for intervention is based on the exponential rise in blood viscosity above that level, which increases thrombotic risk regardless of the cause of erythrocytosis" [15].

Dose Adjustments and Clinical Decision Points

Dose modifications for the combination are driven by individual lab results, not by a blanket interaction rule.

Testosterone enanthate is typically dosed at 100 to 200 mg intramuscularly every 1 to 2 weeks for male hypogonadism, or 50 to 100 mg every 1 to 2 weeks for transmasculine patients targeting mid-male physiologic range [1]. No dose reduction is needed solely because progesterone is co-prescribed.

Oral micronized progesterone is dosed at 100 to 200 mg at bedtime for endometrial protection (in patients also receiving estrogen) or for sleep support. The bedtime timing exploits allopregnanolone's sedative effect therapeutically while minimizing daytime drowsiness [7]. If a patient reports excessive sedation, reducing from 200 mg to 100 mg or switching to vaginal progesterone (which bypasses first-pass metabolism and produces less allopregnanolone) is the standard adjustment [8].

One scenario that may require testosterone dose adjustment: if progesterone is prescribed for its anti-gonadotropic effect (suppressing LH), it could theoretically reduce endogenous testosterone production in patients who retain some testicular function. This is relevant only in patients not fully dependent on exogenous testosterone. In fully replaced hypogonadal men or transmasculine patients post-oophorectomy, this mechanism is irrelevant.

Lipid and Cardiovascular Considerations

The cardiovascular profile of this combination deserves specific attention because both hormones influence lipid metabolism and vascular function through different pathways.

Testosterone replacement therapy lowers HDL cholesterol. The TRAVERSE trial (N=5,246), published in The New England Journal of Medicine in 2023, demonstrated that testosterone replacement in men aged 45 to 80 with hypogonadism and preexisting cardiovascular disease did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo (7.0% vs. 7.3%; hazard ratio 0.96, 95% CI 0.78 to 1.17) [16]. This trial provided reassurance about cardiovascular safety but confirmed the HDL-lowering effect (mean reduction of approximately 2 to 3 mg/dL).

Progesterone, unlike synthetic progestins such as medroxyprogesterone acetate (MPA), is considered lipid-neutral or mildly favorable. The PEPI trial (N=875) showed that micronized progesterone combined with estrogen preserved the HDL-raising effect of estrogen therapy, while MPA partially blunted it [17]. For patients on testosterone who already face HDL reduction, choosing micronized progesterone over synthetic progestins preserves a more favorable lipid profile.

Blood pressure monitoring is practical. Testosterone can raise systolic blood pressure by 3 to 5 mmHg on average, while progesterone's antimineralocorticoid activity may mildly lower it [9]. The net effect varies by patient and requires individualized assessment.

Contraindications and When to Avoid the Combination

Absolute contraindications to testosterone enanthate apply regardless of progesterone co-administration: known breast or prostate cancer (active, hormone-sensitive), hematocrit above 54% at baseline, untreated severe obstructive sleep apnea, uncontrolled heart failure, and desire for fertility (testosterone suppresses spermatogenesis) [1][6].

Absolute contraindications to progesterone include known hypersensitivity to the drug or peanut oil (Prometrium capsules contain peanut oil), active arterial thromboembolic disease, and known or suspected breast cancer [8].

Relative precautions for the combination include a history of thromboembolic events (testosterone increases erythrocytosis risk, and high-dose progestins have thrombotic associations, though micronized progesterone appears safer than synthetic progestins per the ESTHER study) [18], active liver disease (both drugs undergo hepatic metabolism), and unstable mood disorders (both hormones affect neurosteroid pathways).

Patient Counseling Points

Patients starting this combination should receive targeted counseling on five practical issues.

Injection timing and progesterone timing. Take progesterone at bedtime. Testosterone injection day does not need to be coordinated with progesterone dosing.

Sedation warning. Do not drive or operate heavy machinery within 2 hours of taking oral progesterone, especially during the first 2 weeks. If daytime drowsiness persists, contact your prescriber.

Edema and weight. Track body weight weekly for the first month. Report sudden weight gain exceeding 3 to 5 pounds in one week, which may indicate fluid retention requiring evaluation.

Blood draws. Expect lab work at baseline, 8 to 12 weeks, 6 months, and annually. Trough testosterone levels should be drawn the morning of (or the day before) your next scheduled injection.

Signs requiring immediate contact. Severe headache, chest pain, leg swelling or redness (concern for deep vein thrombosis), shortness of breath, or vision changes should prompt immediate medical evaluation. These symptoms could indicate polycythemia-related hyperviscosity or thromboembolic events.